Generate Biomedicines logo
Startup

Generate Biomedicines

See Generate Biomedicines's full profile

BOOK A DEMO
Headquarters

United States

Founded Year

2020

Total Funding

$50.0M

Employees

51 - 200

Status

Active


About Generate Biomedicines

We’ve studied millions of proteins in order to learn the generalizable rules by which nature encodes function. We can use those learned rules to generate novel medicines with specific therapeutic functions.

Headquarters

United States


General Information on Generate Biomedicines

Brand name Generate Biomedicines
Company name Generate Biomedicines Inc.
Website https://generatebiomedicines.com/
Founded year 2020
Employees 51 - 200
Contact [email protected]

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
BOOK A DEMO

Recent News and Activity about Generate Biomedicines

StreetInsider 27.07.2022
Generate Biomedicines Expands Leadership Team with the Addition of Chief Medical Officer Alexandra Snyder, M.D.

July 26, 2022 7:00 AM EDT SOMERVILLE, Mass.--(BUSINESS WIRE)-- Generate Biomedicines, whose machine learning-powered generative biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced that Alexandra Snyder, M.D. has been named Chief Medical Officer to oversee all clinical matters. This press release features multimedia. View the full release ...

Generate Biomedicines news
The Bakersfield 26.07.2022
Generate Biomedicines Expands Leadership Team with the Addition of Chief Medical Officer Alexandra Snyder, M.D. Business Wire Jul 26, 2022 1 hr ago

SOMERVILLE, Mass.--(BUSINESS WIRE)--Jul 26, 2022-- Generate Biomedicines, whose machine learning-powered generative biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced that Alexandra Snyder, M.D. has been named Chief Medical Officer to oversee all clinical matters. This press release features multimedia. View the full release here: ...

AP News 26.07.2022
Generate Biomedicines Expands Leadership Team with the Addition of Chief Medical Officer Alexandra Snyder, M.D.

SOMERVILLE, Mass.--(BUSINESS WIRE)--Jul 26, 2022-- Generate Biomedicines, whose machine learning-powered generative biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced that Alexandra Snyder, M.D. has been named Chief Medical Officer to oversee all clinical matters. This press release features multimedia. View the full release here: ...

Generate Biomedicines news
Manchester Times 25.07.2022
Generate Biomedicines Bolsters Leadership Team With the Addition of Jason Silvers, M.D., J.D., as Chief Financial Officer

Generate Biomedicines, whose machine learning-powered generative biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced that Jason Silvers, M.D., J.D., has been named the company’s Chief Financial Officer, overseeing all financial matters as the company advances into its next stage of growth.

AP News 25.04.2022
Generate Biomedicines Expands Leadership Team With Addition of Sean Martin as Chief Legal Officer and General Counsel

rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced that Sean Martin has been named the company's Chief Legal Officer and General Counsel, overseeing all legal and compliance matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005153/en/ Sean Martin, Chief Legal Officer and General Counsel, ...

Generate Biomedicines news
C&EN - Chemical & Engineering News 21.11.2021
Flagship’s Generate Biomedicines raises $370 million for de novo protein design

Generate Biomedicines, a start-up founded by Flagship Pioneering, has raised $370 million in series B financing to develop its technology for de novo protein design. The company’s goal is to use machine learning to create therapeutic proteins—including antibodies, cytokines, enzymes, and peptides—from scratch for any disease. Generate Biomedicines plans to expand its current staff of 80 employees to 500 over the next 2 years and advance multiple ...